Source: StreetInsider

Press Release: LUMICKS : New Study Highlights Cell Avidity's Power to Provide Insights into the Robustness of T Cell Activation

AMSTERDAM, March 23, 2022 /PRNewswire/ -- LUMICKS, a next generation life science tools company, today announced that a research study published in...

Read full article »

LUMICKS's Competitors | LUMICKS's News | LUMICKS's Financials

Followers on Owler

322

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

Co-Founder & CEO

Olivier Heyning

CEO Approval Rating

90/100

LUMICKS is a Netherland-based life science tools company that develops single-molecule analysis and related products for cancer research applications.